B4V Stock Overview
A life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing in Norway, Germany, Lithuania, France, Italy, rest of Europe, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ArcticZymes Technologies ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 2.19 |
| 52 Week High | NOK 3.74 |
| 52 Week Low | NOK 1.86 |
| Beta | 0.93 |
| 11 Month Change | 5.30% |
| 3 Month Change | -10.08% |
| 1 Year Change | -34.97% |
| 33 Year Change | -76.21% |
| 5 Year Change | 450.38% |
| Change since IPO | -22.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| B4V | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.9% | -1.8% | -0.1% |
| 1Y | -35.0% | -18.5% | 2.4% |
Return vs Industry: B4V underperformed the German Biotechs industry which returned -18.5% over the past year.
Return vs Market: B4V underperformed the German Market which returned 2.4% over the past year.
Price Volatility
| B4V volatility | |
|---|---|
| B4V Average Weekly Movement | 7.4% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: B4V has not had significant price volatility in the past 3 months.
Volatility Over Time: B4V's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 61 | Michael Akoh | www.arcticzymes.com |
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing in Norway, Germany, Lithuania, France, Italy, rest of Europe, the United States, and internationally. The company offers shrimp alkaline phosphatase for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays; salt active nuclease for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; double-strand specific DNases and derived kits for the removal of double stranded DNA; DNA/RNA polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; and ligases for joining nucleic acids. It serves the molecular tools research and diagnostics, and biomanufacturing markets.
ArcticZymes Technologies ASA Fundamentals Summary
| B4V fundamental statistics | |
|---|---|
| Market cap | €111.36m |
| Earnings (TTM) | €1.53m |
| Revenue (TTM) | €10.35m |
72.6x
P/E Ratio10.8x
P/S RatioIs B4V overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| B4V income statement (TTM) | |
|---|---|
| Revenue | NOK 118.47m |
| Cost of Revenue | NOK 5.30m |
| Gross Profit | NOK 113.18m |
| Other Expenses | NOK 95.62m |
| Earnings | NOK 17.56m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 22, 2024
| Earnings per share (EPS) | 0.35 |
| Gross Margin | 95.53% |
| Net Profit Margin | 14.82% |
| Debt/Equity Ratio | 0% |
How did B4V perform over the long term?
See historical performance and comparison